A Study Evaluating Tolerability, Pharmacokinetics, and Preliminary Efficacy of HC-1119 in Patients.
Status:
Completed
Trial end date:
2019-08-28
Target enrollment:
Participant gender:
Summary
This is a phase I study evaluating tolerability, pharmacokinetics, and preliminary efficacy
of HC-1119 in patients with metastatic castration-resistant prostate cancer. The study
objective is to study the tolerability, safety, and dose-limiting toxicities (DLT) of HC-1119
in patients with mCRPC.
Phase:
Phase 1
Details
Lead Sponsor:
Hinova Pharmaceuticals Inc. Sichuan Haisco Pharmaceutical Group Co., Ltd.